• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Compass Therapeutics Inc.

    2/13/26 4:30:02 PM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CMPX alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    Compass Therapeutics, Inc.

    (Name of Issuer)


    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)


    20454B104

    (CUSIP Number)


    12/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    20454B104


    1Names of Reporting Persons

    Blackstone Annex Master Fund L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,447,820.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,447,820.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,447,820.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    1.4 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    20454B104


    1Names of Reporting Persons

    Spruce Street Aggregator L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    3,678,362.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    3,678,362.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,678,362.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    2.1 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    20454B104


    1Names of Reporting Persons

    Blackstone Alternative Asset Management Associates LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    6,126,182.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    6,126,182.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    6,126,182.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    3.4 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    20454B104


    1Names of Reporting Persons

    Blackstone Holdings II L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    6,126,182.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    6,126,182.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    6,126,182.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    3.4 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    20454B104


    1Names of Reporting Persons

    Blackstone Holdings I/II GP L.L.C.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    6,126,182.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    6,126,182.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    6,126,182.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    3.4 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    20454B104


    1Names of Reporting Persons

    Blackstone Inc.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    6,126,182.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    6,126,182.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    6,126,182.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    3.4 %
    12Type of Reporting Person (See Instructions)

    CO


    SCHEDULE 13G

    CUSIP No.
    20454B104


    1Names of Reporting Persons

    Blackstone Group Management L.L.C.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    6,126,182.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    6,126,182.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    6,126,182.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    3.4 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    20454B104


    1Names of Reporting Persons

    Stephen A. Schwarzman
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    6,126,182.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    6,126,182.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    6,126,182.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    3.4 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Compass Therapeutics, Inc.
    (b)Address of issuer's principal executive offices:

    80 Guest Street, Suite 601, Boston, MA 02135
    Item 2. 
    (a)Name of person filing:

    This Schedule 13G is being filed by Blackstone Annex Master Fund L.P. ("Annex Fund"), Spruce Street Aggregator L.P. ("Spruce"), Blackstone Alternative Asset Management Associates LLC ("BAAMA"), Blackstone Holdings II L.P. ("Holdings II"), Blackstone Holdings I/II GP L.L.C. ("Holdings GP"), Blackstone Inc. ("Blackstone"), Blackstone Group Management L.L.C. ("Blackstone Management"), and Stephen A. Schwarzman (together with Annex Fund, Spruce, BAAMA, Holdings II, Holdings GP, Blackstone and Blackstone Management, the "Reporting Persons").
    (b)Address or principal business office or, if none, residence:

    The principal business address of each of the Reporting Persons is: 345 Park Avenue New York, NY 10154
    (c)Citizenship:

    Annex Fund is a Cayman Islands limited partnership. Spruce is a Cayman Islands exempted limited partnership. BAAMA is a limited liability company organized under the laws of the State of Delaware. Holdings II is a limited partnership organized under the laws of the State of Delaware. Holdings GP is a limited liability company organized under the laws of the State of Delaware. Blackstone is a corporation organized under the laws of the State of Delaware. Blackstone Management is a limited liability company organized under the laws of the State of Delaware. Mr. Schwarzman is a citizen of the United States of America.
    (d)Title of class of securities:

    Common Stock, $0.0001 par value per share
    (e)CUSIP No.:

    20454B104
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    Items 5 through 9 and 11 of each of the cover pages to this Schedule 13G are incorporated herein by reference. As of December 31, 2025, Annex Fund directly holds 2,447,820 shares of Common Stock, $0.0001 par value per share per share ("Common Stock") of Compass Therapeutics, Inc. (the "Issuer") and Spruce directly holds 3,678,362 shares of Common Stock. BAAMA is the general partner of the Annex Fund and Spruce. Holdings II is the sole member of BAAMA. Holdings GP is the general partner of Holdings II. Blackstone is the sole member of Holdings GP. Blackstone Management is the sole holder of the Series II preferred stock of Blackstone. Blackstone Management is wholly owned by its senior managing directors and controlled by its founder, Stephen A. Schwarzman. Each Reporting Person may be deemed to beneficially own the Common Stock of the Issuer directly or indirectly controlled by it or him, but neither the filing of this Schedule 13G nor any of its contents shall be deemed to constitute an admission that any such Reporting Person (other than any Reporting Person to the extent they directly hold Issuer securities) is the beneficial owner of Common Stock of the Issuer referred to herein for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended (the "Act"), or for any other purpose and each of the Reporting Persons expressly disclaims beneficial ownership of such shares of Common Stock. The filing of this statement should not be construed to be an admission that any member of the Reporting Persons are members of a "group" for the purposes of Section 13(d) and 13(g) of the Act.
    (b)Percent of class:

    Each of the Reporting Persons may be deemed to be the beneficial owner of the percentage of shares of Common Stock listed on such Reporting Person's cover page. Calculations are based on 177,572,498 shares of Common Stock of the Issuer outstanding as of September 30, 2025, as disclosed in the Issuer's Registration Statement on Form S-3 filed with the Securities and Exchange Commission on December 30, 2025. As of December 31, 2025, Reporting Persons no longer beneficially own more than five percent of the Common Stock. This filing represents an exit filing for the Reporting Persons.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    See each cover page hereof.

     (ii) Shared power to vote or to direct the vote:

    See each cover page hereof.

     (iii) Sole power to dispose or to direct the disposition of:

    See each cover page hereof.

     (iv) Shared power to dispose or to direct the disposition of:

    See each cover page hereof.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Blackstone Annex Master Fund L.P.
     
    Signature:/s/ Stephen O'Connor
    Name/Title:By: Blackstone Alternative Asset Management Associates LLC, its general partner, By: Stephen O'Connor, Authorized Person
    Date:02/13/2026
     
    Spruce Street Aggregator L.P.
     
    Signature:/s/ Stephen O'Connor
    Name/Title:By: Blackstone Alternative Asset Management Associates LLC, its general partner, By: Stephen O'Connor, Authorized Person
    Date:02/13/2026
     
    Blackstone Alternative Asset Management Associates LLC
     
    Signature:/s/ Stephen O'Connor
    Name/Title:Stephen O'Connor, Authorized Person
    Date:02/13/2026
     
    Blackstone Holdings II L.P.
     
    Signature:/s/ Victoria Portnoy
    Name/Title:Victoria Portnoy Managing Director - Assistant Secretary
    Date:02/13/2026
     
    Blackstone Holdings I/II GP L.L.C.
     
    Signature:/s/ Victoria Portnoy
    Name/Title:Victoria Portnoy Managing Director - Assistant Secretary
    Date:02/13/2026
     
    Blackstone Inc.
     
    Signature:/s/ Victoria Portnoy
    Name/Title:Victoria Portnoy Managing Director - Assistant Secretary
    Date:02/13/2026
     
    Blackstone Group Management L.L.C.
     
    Signature:/s/ Victoria Portnoy
    Name/Title:Victoria Portnoy Managing Director - Assistant Secretary
    Date:02/13/2026
     
    Stephen A. Schwarzman
     
    Signature:/s/ Stephen A. Schwarzman
    Name/Title:Stephen A. Schwarzman
    Date:02/13/2026
    Get the next $CMPX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CMPX

    DatePrice TargetRatingAnalyst
    2/13/2026$15.00Buy
    Craig Hallum
    1/5/2026Outperform
    William Blair
    12/3/2025$10.00Mkt Outperform
    Citizens JMP
    12/3/2025$10.00Buy
    Canaccord Genuity
    12/3/2025Overweight
    Cantor Fitzgerald
    7/1/2025$9.00Outperform
    Raymond James
    4/2/2025$6.00Market Perform → Outperform
    Leerink Partners
    2/24/2025$12.00Buy
    Guggenheim
    More analyst ratings

    $CMPX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    The $185B Cancer Surge: Why the FDA's Fast-Track Pivot is Scaling a New Immunotherapy Era

    VANCOUVER, British Columbia, Jan. 14, 2026 (GLOBE NEWSWIRE) -- USANewsGroup.com News Commentary – The global immuno-oncology market is set to explode from its current $35 billion level to a massive $185.69 billion by 2035 as the industry moves toward the coordinated activation of the immune system[1]. This surge is being accelerated by the $69.16 billion genomics revolution, which is now integrating advanced profiling into every oncology workflow to pick winning treatments[2]. This strategic push for registration-ready precision assets fuels the 2026 investment case for Oncolytics Biotech Inc. (NASDAQ:ONCY), ImmunityBio (NASDAQ:IBRX), OS Therapies (NYSE-A: OSTX), BioNTech SE (NASDAQ:BNTX),

    1/14/26 10:39:59 AM ET
    $BNTX
    $CMPX
    $IBRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced it granted stock options to two new employees under the Company's 2025 Inducement Plan and as a material inducement to their employment in accordance with Nasdaq Listing Rule 5635(c)(4). The Company granted non-qualified stock options to purchase 1,000,000 shares of common stock to its newly appointed Chief Commercial Officer, Arjun Prasad, and also granted non-qualified stock options to purchase 1,000,000 shares of common stock to its newly appoi

    1/5/26 4:30:00 PM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Compass Therapeutics Announces Key Leadership Appointments

    BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced the appointments of Arjun Prasad, MBA, MPH as Chief Commercial Officer and Cynthia Sirard, MD as Chief Medical Officer, both effective as of January 1, 2026. "We are thrilled to welcome Arjun and Cyndi to the Compass team. They are highly accomplished leaders with decades of commercial and clinical development experience," said Thomas Schuetz, MD, PhD, CEO of Compass and Vice Chairman of the Board of Directors. "Arjun's world-class expertise in on

    1/5/26 8:00:00 AM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CMPX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF EXECUTIVE OFFICER Schuetz Thomas J. covered exercise/tax liability with 36,687 shares, decreasing direct ownership by 0.55% to 6,603,336 units (SEC Form 4)

    4 - Compass Therapeutics, Inc. (0001738021) (Issuer)

    2/10/26 8:00:15 AM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CHIEF EXECUTIVE OFFICER Schuetz Thomas J. covered exercise/tax liability with 46,777 shares, decreasing direct ownership by 0.70% to 6,640,023 units (SEC Form 4)

    4 - Compass Therapeutics, Inc. (0001738021) (Issuer)

    1/12/26 8:00:13 AM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CFO Shin Barry was granted 125,000 shares, increasing direct ownership by 31% to 525,000 units (SEC Form 4)

    4 - Compass Therapeutics, Inc. (0001738021) (Issuer)

    1/5/26 4:33:59 PM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CMPX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Craig Hallum initiated coverage on Compass Therapeutics with a new price target

    Craig Hallum initiated coverage of Compass Therapeutics with a rating of Buy and set a new price target of $15.00

    2/13/26 8:35:30 AM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    William Blair initiated coverage on Compass Therapeutics

    William Blair initiated coverage of Compass Therapeutics with a rating of Outperform

    1/5/26 8:57:39 AM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Citizens JMP initiated coverage on Compass Therapeutics with a new price target

    Citizens JMP initiated coverage of Compass Therapeutics with a rating of Mkt Outperform and set a new price target of $10.00

    12/3/25 8:37:10 AM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CMPX
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Compass Therapeutics Inc.

    SCHEDULE 13G/A - Compass Therapeutics, Inc. (0001738021) (Subject)

    2/13/26 4:30:02 PM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form EFFECT filed by Compass Therapeutics Inc.

    EFFECT - Compass Therapeutics, Inc. (0001738021) (Filer)

    1/8/26 12:15:25 AM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Compass Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

    8-K - Compass Therapeutics, Inc. (0001738021) (Filer)

    1/6/26 8:00:54 AM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CMPX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF EXECUTIVE OFFICER Schuetz Thomas J. bought $21,100 worth of shares (10,000 units at $2.11), increasing direct ownership by 0.15% to 6,480,825 units (SEC Form 4)

    4 - Compass Therapeutics, Inc. (0001738021) (Issuer)

    5/27/25 3:24:21 PM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Gen Counsel & Corporate Sec Anderman Jonathan bought $30,800 worth of shares (20,000 units at $1.54), increasing direct ownership by 2,000% to 21,000 units (SEC Form 4)

    4 - Compass Therapeutics, Inc. (0001738021) (Issuer)

    4/8/25 9:30:55 AM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CHIEF ACCOUNTING OFFICER Lerner Neil bought $28,400 worth of shares (20,000 units at $1.42), increasing direct ownership by 7% to 320,000 units (SEC Form 4)

    4 - Compass Therapeutics, Inc. (0001738021) (Issuer)

    4/8/25 9:25:57 AM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CMPX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Compass Therapeutics Inc.

    SC 13G/A - Compass Therapeutics, Inc. (0001738021) (Subject)

    11/14/24 10:00:35 AM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Compass Therapeutics Inc.

    SC 13G - Compass Therapeutics, Inc. (0001738021) (Subject)

    8/2/24 4:15:57 PM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13D/A filed by Compass Therapeutics Inc. (Amendment)

    SC 13D/A - Compass Therapeutics, Inc. (0001738021) (Subject)

    3/22/24 4:59:51 PM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CMPX
    Financials

    Live finance-specific insights

    View All

    Compass Therapeutics Reports 2025 Second Quarter Financial Results and Provides Corporate Update

    In the ongoing Phase 2/3 study of tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer, fewer deaths have been observed than originally projected. We believe this may suggest that tovecimig could be affecting overall survival in the patient population. As a result, the analysis of the secondary endpoints, including overall survival, is now expected in Q1 2026.In the ongoing Phase 1 dose-escalation study of CTX-8371 (PD-1 x PD-L1 bispecific antibody) in patients treated in the post-checkpoint inhibitor setting, two deep and confirmed partial responses have been observed to date. A patient with non-small cell lung cancer had a 100% reduction in target le

    8/11/25 7:00:00 AM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Compass Therapeutics to Present Second Quarter Financial Results and Provide Business Update on August 11, 2025

    BOSTON, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, will release its financial results for the quarter ended June 30, 2025 and host a webcast and conference call to provide an update on the ongoing tovecimig Phase 2/3 study, clinical data for CTX-8371 and preclinical data for CTX-10726, on Monday, August 11, 2025, at 8:00 a.m. ET. Call Details: Date: Monday, August 11, 2025 Time: 8:00 AM ET Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1727543&tp_key=955a2c2f4d Dial-In: 1-877-407-9716 (US), 1-201-493-6779 (International), 13754954 (Co

    8/8/25 4:01:00 PM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Compass Therapeutics to Host Conference Call Highlighting Clinical Data from CTX-009

    Call scheduled for Wednesday, May 4, 2022 at 8:00 a.m. ET Key Opinion Leader to Participate BOSTON, May 03, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer, today announced that it will host a webinar on Wednesday, May 4, 2022 at 8:00 a.m. ET to review clinical data from its ongoing Phase 2 clinical trial assessing CTX-009. A Key Opinion Leader will join management for the discussion. Webinar Details:   Date:  May 04, 2022   Time: 8:00 a.m. ET   Webcast: Registration Link   Replay availability: A replay will be available on the Compass website for 6 months. Abo

    5/3/22 4:01:00 PM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CMPX
    Leadership Updates

    Live Leadership Updates

    View All

    The $185B Cancer Surge: Why the FDA's Fast-Track Pivot is Scaling a New Immunotherapy Era

    VANCOUVER, British Columbia, Jan. 14, 2026 (GLOBE NEWSWIRE) -- USANewsGroup.com News Commentary – The global immuno-oncology market is set to explode from its current $35 billion level to a massive $185.69 billion by 2035 as the industry moves toward the coordinated activation of the immune system[1]. This surge is being accelerated by the $69.16 billion genomics revolution, which is now integrating advanced profiling into every oncology workflow to pick winning treatments[2]. This strategic push for registration-ready precision assets fuels the 2026 investment case for Oncolytics Biotech Inc. (NASDAQ:ONCY), ImmunityBio (NASDAQ:IBRX), OS Therapies (NYSE-A: OSTX), BioNTech SE (NASDAQ:BNTX),

    1/14/26 10:39:59 AM ET
    $BNTX
    $CMPX
    $IBRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Compass Therapeutics Announces Key Leadership Appointments

    BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced the appointments of Arjun Prasad, MBA, MPH as Chief Commercial Officer and Cynthia Sirard, MD as Chief Medical Officer, both effective as of January 1, 2026. "We are thrilled to welcome Arjun and Cyndi to the Compass team. They are highly accomplished leaders with decades of commercial and clinical development experience," said Thomas Schuetz, MD, PhD, CEO of Compass and Vice Chairman of the Board of Directors. "Arjun's world-class expertise in on

    1/5/26 8:00:00 AM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Compass Therapeutics Appoints Biopharmaceutical Industry Leader Barry Shin as Chief Financial Officer

    BOSTON, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced the appointment of Barry Shin as Chief Financial Officer, as of December 9, 2024. Mr. Shin is a veteran biopharmaceutical leader with over 20 years of experience as a finance and operations executive, investment banker, and corporate advisor. "We are delighted to welcome Barry to Compass during this pivotal and exciting time for the company," said Thomas Schuetz, MD, PhD, CEO of Compass and Vice Chairman of the Board of Directors. "We have severa

    12/10/24 8:00:00 AM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care